每日一次的奈韦拉平缓释制剂用于治疗HIV感染的临床效用及消费者考量
Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment.
作者信息
Yone Eric W Pefura, Kengne André P
机构信息
Department of Internal Medicine and Subspecialties, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Cameroon ; Approved Centre for HIV Treatment and Pneumology Service, Yaounde Jamot Hospital, Cameroon.
出版信息
HIV AIDS (Auckl). 2012;4:181-4. doi: 10.2147/HIV.S24432. Epub 2012 Dec 5.
Abstract
An extended-release formulation of nevirapine (NVP-XR) has been developed with the aim of simplifying antiretroviral treatment regimens and improving patients' adherence with a single daily intake. The VERxVE and TRANxITION clinical trials have demonstrated the noninferiority of NVP-XR compared with nevirapine immediate-release (NVP-IR) on viral load after 24 and 48 months of treatment. The tolerance profiles of NVP-XR and NVP-IR are similar. Simplifying the treatment dosage for NVP would likely improve adherence to antiretroviral treatments.
摘要
已开发出奈韦拉平缓释制剂（NVP-XR），旨在简化抗逆转录病毒治疗方案，并通过每日一次服药提高患者的依从性。VERxVE和TRANxITION临床试验已证明，在治疗24个月和48个月后，NVP-XR与奈韦拉平速释制剂（NVP-IR）相比，在病毒载量方面具有非劣效性。NVP-XR和NVP-IR的耐受性特征相似。简化奈韦拉平的治疗剂量可能会提高对抗逆转录病毒治疗的依从性。
相似文献
1
Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment.
HIV AIDS (Auckl). 2012;4:181-4. doi: 10.2147/HIV.S24432. Epub 2012 Dec 5.
2
Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
HIV Med. 2012 Apr;13(4):236-44. doi: 10.1111/j.1468-1293.2011.00969.x. Epub 2011 Dec 4.
3
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.
Antivir Ther. 2011;16(5):759-69. doi: 10.3851/IMP1803.
4
Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan.
BMC Infect Dis. 2017 Apr 11;17(1):261. doi: 10.1186/s12879-017-2371-3.
5
Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection.
HIV Clin Trials. 2017 Nov-Dec;18(5-6):189-195. doi: 10.1080/15284336.2017.1386811.
6
Guidelines for the use of extended-release nevirapine in HIV-infected patients.
Expert Opin Pharmacother. 2011 Dec;12(17):2713-8. doi: 10.1517/14656566.2011.630391. Epub 2011 Oct 29.
7
Nevirapine extended-release for the treatment of HIV-1 infection.
Expert Rev Anti Infect Ther. 2012 Jan;10(1):21-30. doi: 10.1586/eri.11.145.
8
Considerations on the new nevirapine: switching patients from twice-daily to once-daily.
J Int Assoc Provid AIDS Care. 2013 May-Jun;12(3):154-6. doi: 10.1177/2325957412473648. Epub 2013 Feb 28.
9
Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.
Expert Opin Drug Metab Toxicol. 2011 Apr;7(4):495-503. doi: 10.1517/17425255.2011.565331. Epub 2011 Mar 20.
10
Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.
Clin Ther. 2011 Sep;33(9):1308-20. doi: 10.1016/j.clinthera.2011.08.003. Epub 2011 Aug 27.
本文引用的文献
1
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.
JAMA. 2012 Jul 25;308(4):387-402. doi: 10.1001/jama.2012.7961.
2
NNRTIs: pharmacological data.
Med Mal Infect. 2012 Jul;42(7):287-95. doi: 10.1016/j.medmal.2012.05.004. Epub 2012 Jun 22.
3
Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
HIV Med. 2012 Apr;13(4):236-44. doi: 10.1111/j.1468-1293.2011.00969.x. Epub 2011 Dec 4.
4
Guidelines for the use of extended-release nevirapine in HIV-infected patients.
Expert Opin Pharmacother. 2011 Dec;12(17):2713-8. doi: 10.1517/14656566.2011.630391. Epub 2011 Oct 29.
5
Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
Clin Infect Dis. 2011 Oct;53(7):716-24. doi: 10.1093/cid/cir447.
6
Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.
Clin Ther. 2011 Sep;33(9):1308-20. doi: 10.1016/j.clinthera.2011.08.003. Epub 2011 Aug 27.
7
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.
Antivir Ther. 2011;16(5):759-69. doi: 10.3851/IMP1803.
8
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.
JAMA. 2010 Jul 21;304(3):321-33. doi: 10.1001/jama.2010.1004.
9
Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial).
Eur J Med Res. 2009;14(12):516-9. doi: 10.1186/2047-783x-14-12-516.
10
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
J Antimicrob Chemother. 2009 Feb;63(2):380-8. doi: 10.1093/jac/dkn471. Epub 2008 Nov 25.
Zotero 插件